Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) saw an uptick in trading volume on Thursday . 239,783 shares changed hands during trading, a decline of 2% from the previous session’s volume of 245,352 shares.The stock last traded at $14.51 and had previously closed at $13.67.

A number of brokerages have issued reports on ADMS. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Cowen and Company reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a report on Thursday, May 12th. Mizuho raised Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating in a report on Monday, June 13th. JMP Securities reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $44.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, June 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Adamas Pharmaceuticals has an average rating of “Buy” and an average price target of $32.00.

The stock’s market capitalization is $323.67 million. The company has a 50 day moving average price of $14.23 and a 200 day moving average price of $15.29.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP increased its stake in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned approximately 0.38% of Adamas Pharmaceuticals worth $1,966,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.